1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €379.77 (+34,424.55%). The median is €379.77 (+34,424.55%).
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 1.07M | 280.47% |
| Gross profit | 27.87K | 83.73% |
| Net profit | -6.11M | 46.16% |
| EBITDA | -6.26M | 42.20% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €538.94K |
Number of shares | 524.73K |
52-week high/low | €400.83 - €0.73 |
| Dividends | No |
Beta | 1.55 |
P/E ratio | -0.01 |
PEG ratio | 0.00 |
P/B ratio | -0.07 |
P/S ratio | 0.10 |
Company profile
| Name | NEWBORN ACQ. CORP. |
| CEO | Gregory Poilasne |
| Employees | 45 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | NVVE |
Discover assets
Shareholders of NEWBORN ACQ. CORP. also invest in the following assets
